Semi-annual Report for 2026
Filed with SSE · · 202 pages · Chinese
BrightGene Bio-Medical Technology Co. Ltd. on 6ix
Earlier from BrightGene Bio-Medical Technology
- Announcement on Voluntary Disclosure of the Phase I Clinical Trial Data of BGM1812 Injection for Weight Loss Indication
- Voluntary Disclosure Announcement on Acquisition of Drug Registration Certificate for Tiotropium Bromide Inhalation Spray by a Controlled Subsidiary
- Voluntary Disclosure Announcement on Acquisition of Drug Registration Certificate for Tiotropium Bromide and Olodaterol Inhalation Spray by a Controlled Subsidiary
- Announcement on the Board Secretary's Obtaining the Certificate of Qualification Training and Officially Assuming Duties
- Announcement on Appointment of Secretary of the Board of Directors
Later from BrightGene Bio-Medical Technology
- Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry
- Announcement on Results of Shareholding Reduction by Shareholder
- Announcement on Resolutions of the 25th Meeting of the 4th Board of Directors
- (688166)"BrightGene Bio-Medical Technology Co., Ltd."Announcement on Voluntary Disclosure of Receipt of the Clinical Trial Approval Notice for BGM0504 Tablets
- (688166)"BrightGene Bio-Medical Technology Co., Ltd."Report for Q3 2026
Follow BrightGene Bio-Medical Technology into a list and get an email when it puts out news.
Follow BrightGene Bio-Medical Technology